Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market

Neurobiological Technologies Announces Intent to File Form 25 to Delist Common
Stock From the NASDAQ Capital Market

EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted
written notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends to
file a Form 25 with the Securities and Exchange Commission ("SEC") on or about
October 28, 2009 to effect the voluntary delisting of its common stock from
NASDAQ, if NTI's stockholders approve the dissolution of the company pursuant
to a Plan of Complete Liquidation and Dissolution at the special meeting of
stockholders planned for Tuesday, October 27, 2009.

Details of NTI's plans to pay an extraordinary dividend, delist its common
stock from the Nasdaq Capital Market, discontinue recording transfers of
stock, cease its reporting obligations under the Securities Exchange Act of
1934, as amended, and distribute its net cash to stockholders can be found in
a definitive proxy statement filed with the SEC on September 22, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically
focused on developing investigational drugs for central nervous system
conditions.

SOURCE Neurobiological Technologies, Inc.

Matthew M. Loar, CFO of Neurobiological Technologies, Inc., +1-510-595-6000